# Shizuo Yamada

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5227231/publications.pdf

Version: 2024-02-01

| 80 | 1,800 | 236833 | 315616 |
|---|---|---|---|
| papers | citations | 25 h-index | 38 g-index |

| 81 | 81 | 81 | 1217 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | High affinity renal [3H]flunitrazepam binding: Characterization, localization, and alteration in hypertension. Life Sciences, 1981, 28, 991-998. | 2.0 | 102 |
| 2 | Regional adaptation of muscarinic receptors and choline uptake in brain following repeated administration of diisopropylfluorophosphate and atropine. Brain Research, 1983, 268, 315-320. | 1.1 | 82 |
| 3 | Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sciences, 2004, 75, 2971-2981. | 2.0 | 80 |
| 4 | Neuroprotective effect of nobiletin on cerebral ischemiaâ€“reperfusion injury in transient middle cerebral artery-occluded rats. Brain Research, 2014, 1559, 46-54. | 1.1 | 76 |
| 5 | Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Molecular Brain Research, 2005, 133, 6-11. | 2.5 | 73 |
| 6 | Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. , 2018, 189, 130-148. | | 68 |
| 7 | Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonists. Life Sciences, 1994, 54, 1845-1854. | 2.0 | 54 |
| 8 | Human Muscarinic Receptor Binding Characteristics of Antimuscarinic Agents to Treat Overactive Bladder. Journal of Urology, 2006, 175, 365-369. | 0.2 | 54 |
| 9 | COMPARATIVE STUDY ON?1-ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 405-411. | 0.9 | 53 |
| 10 | Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacologica Sinica, 2009, 30, 271-281. | 2.8 | 51 |
| 11 | Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. British Journal of Pharmacology, 2005, 145, 219-227. | 2.7 | 48 |
| 12 | Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M<sub>1</sub>â€“M<sub>5</sub> receptor single knockout mice. British Journal of Pharmacology, 2009, 156, 1147-1153. | 2.7 | 45 |
| 13 | Isolation and Pharmacological Characterization of Fatty Acids from Saw Palmetto Extract. Analytical Sciences, 2009, 25, 553-557. | 0.8 | 45 |
| 14 | Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 365-371. | 1.3 | 45 |
| 15 | In Vivo Quantitative Autoradiographic Analysis of Brain Muscarinic Receptor Occupancy by Antimuscarinic Agents for Overactive Bladder Treatment. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 774-781. | 1.3 | 41 |
| 16 | Pharmacologically Relevant Receptor Binding Characteristics and 5.ALPHA.-Reductase Inhibitory Activity of Free Fatty Acids Contained in Saw Palmetto Extract. Biological and Pharmaceutical Bulletin, 2009, 32, 646-650. | 0.6 | 38 |
| 17 | Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1137-1145. | 1.3 | 37 |
| 18 | DEMONSTRATION OF BLADDER SELECTIVE MUSCARINIC RECEPTOR BINDING BY INTRAVESICAL OXYBUTYNIN TO TREAT OVERACTIVE BLADDER. Journal of Urology, 2004, 172, 2059-2064. | 0.2 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Binding characteristics of naftopidil and Î±1-adrenoceptor antagonists to prostatic Î±-adrenoceptors in benign prostatic hypertrophy. Life Sciences, 1992, 50, 127-135. | 2.0 | 32 |
| 20 | The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Bladder Selectivity Based on In Vivo Drugâ€"Receptor Binding Characteristics of Antimuscarinic Agents for Treatment of Overactive Bladder. Journal of Pharmacological Sciences, 2010, 112, 142-150. | 1.1 | 32 |
| 21 | EFFECTS OF SAW PALMETTO EXTRACT ON MICTURITION REFLEX OF RATS AND ITS AUTONOMIC RECEPTOR BINDING ACTIVITY. Journal of Urology, 2005, 173, 1395-1399. | 0.2 | 30 |
| 22 | Bladder Angiotensin-II Receptors: Characterization and Alteration in Bladder Outlet Obstruction. European Urology, 2009, 55, 482-490. | 0.9 | 29 |
| 23 | Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sciences, 2010, 87, 175-180. | 2.0 | 28 |
| 24 | In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sciences, 2006, 80, 127-132. | 2.0 | 27 |
| 25 | Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. European Journal of Pharmacology, 2006, 529, 157-163. | 1.7 | 26 |
| 26 | Muscarinic and Alpha 1-Adrenergic Receptor Binding Characteristics of Saw Palmetto Extract in Rat Lower Urinary Tract. Urology, 2007, 69, 1216-1220. | 0.5 | 26 |
| 27 | Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: A monkey PET study with [11C](+)3-MPB. NeuroImage, 2011, 58, 1-9. | 2.1 | 26 |
| 28 | Î±1-Adrenoceptors in the Urinary Tract. Handbook of Experimental Pharmacology, 2011, , 283-306. | 0.9 | 25 |
| 29 | Ex vivo occupancy by tamsulosin of Î±1-adrenoceptors in rat tissues in relation to the plasma concentration. Life Sciences, 1998, 63, 2147-2155. | 2.0 | 24 |
| 30 | Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. Neuroscience Letters, 2008, 436, 81-84. | 1.0 | 24 |
| 31 | In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3 H]N/OFQ and [35 S]GTPÎ³ S in rat brain and spinal cord. British Journal of Pharmacology, 2003, 139, 1462-1468. | 2.7 | 23 |
| 32 | Comparative Evaluation of Exocrine Muscarinic Receptor Binding Characteristics and Inhibition of Salivation of Solifenacin in Mice. Biological and Pharmaceutical Bulletin, 2006, 29, 1397-1400. | 0.6 | 23 |
| 33 | RATIONALE FOR THE USE OF a-BLOCKERS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH). International Journal of Urology, 1994, 1, 203-211. | 0.5 | 20 |
| 34 | In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. Life Sciences, 2005, 76, 2445-2456. | 2.0 | 20 |
| 35 | Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain. Life Sciences, 2007, 80, 2454-2460. | 2.0 | 19 |
| 36 | [ 3 H]Bunazosin, a Novel Selective Radioligand of Alpha 1 Adrenoceptors in Human Prostates. Journal of Urology, 1991, 146, 877-880. | 0.2 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | In vivo receptor binding of novel Î±1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Life Sciences, 1998, 62, 1585-1589. | 2.0 | 17 |
| 38 | Prediction of .ALPHA.1-Adrenoceptor Occupancy in the Human Prostate from Plasma Concentrations of Silodosin, Tamsulosin and Terazosin to Treat Urinary Obstruction in Benign Prostatic Hyperplasia. Biological and Pharmaceutical Bulletin, 2007, 30, 1237-1241. | 0.6 | 16 |
| 39 | Comparative Evaluation of Central Muscarinic Receptor Binding Activity by Oxybutynin, Tolterodine and Darifenacin Used to Treat Overactive Bladder. Journal of Urology, 2007, 177, 766-770. | 0.2 | 16 |
| 40 | Improvement by Phytotherapeutic Agent of Detrusor Overactivity, Down-Regulation of Pharmacological Receptors and Urinary Cytokines in Rats with Cyclophosphamide Induced Cystitis. Journal of Urology, 2013, 189, 1123-1129. | 0.2 | 16 |
| 41 | Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis ofIn VivoDrug-Receptor Binding. International Neurourology Journal, 2012, 16, 107. | 0.5 | 16 |
| 42 | Muscarinic Receptor Binding Characteristics in Rat Tissues after Oral Administration of Oxybutynin and Propiverine.. Biological and Pharmaceutical Bulletin, 2001, 24, 491-495. | 0.6 | 15 |
| 43 | TheN-Oxide Metabolite Contributes to Bladder Selectivity Resulting from Oral Propiverine: Muscarinic Receptor Binding and Pharmacokinetics. Drug Metabolism and Disposition, 2010, 38, 1314-1321. | 1.7 | 14 |
| 44 | In vivo receptor binding of benidipine and amlodipine in mesenteric arteries and other tissues of spontaneously hypertensive rats. Life Sciences, 2002, 70, 1999-2011. | 2.0 | 12 |
| 45 | Î±<sub>1</sub>â€Adrenoceptors and muscarinic receptors in voiding function â€“ binding characteristics of therapeutic agents in relation to the pharmacokinetics. British Journal of Clinical Pharmacology, 2011, 72, 205-217. | 1.1 | 12 |
| 46 | Vasorelaxant effects of benzodiazepines, non-benzodiazepine sedative-hypnotics, and tandospirone on isolated rat arteries. European Journal of Pharmacology, 2021, 892, 173744. | 1.7 | 12 |
| 47 | Urodynamics and bladder muscarinic receptors in rats with cerebral infarction and bladder outlet obstruction. Neuroscience Letters, 2007, 414, 80-84. | 1.0 | 11 |
| 48 | Loss of Muscarinic and Purinergic Receptors in Urinary Bladder of Rats With Hydrochloric Acid-induced Cystitis. Urology, 2010, 76, 1017.e7-1017.e12. | 0.5 | 11 |
| 49 | Receptor occupancy in myocardium, adrenal cortex, and brain by TH-142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect. Pharmaceutical Research, 1998, 15, 911-917. | 1.7 | 10 |
| 50 | Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. European Journal of Pharmacology, 2009, 615, 201-206. | 1.7 | 10 |
| 51 | Beneficial effects of a nobiletinâ€rich formulated supplement of Sikwasa (C. depressa) peel on cognitive function in elderly Japanese subjects; A multicenter, randomized, doubleâ€blind, placeboâ€controlled study. Food Science and Nutrition, 2021, 9, 6844-6853. | 1.5 | 10 |
| 52 | In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 463-471. | 1.4 | 9 |
| 53 | Characterization of Muscarinic Receptors in the Human Bladder Mucosa: Direct Quantification of Subtypes Using 4-DAMP Mustard. Urology, 2011, 78, 721.e7-721.e12. | 0.5 | 9 |
| 54 | Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder. International Journal of Urology, 2021, 28, 1298-1303. | 0.5 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Urinary Excretion Contributes to Long-Lasting Blockade of Bladder Muscarinic Receptors by Imidafenacin: Effect of Bilateral Ureteral Ligation. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 69-74. | 1.3 | 8 |
| 56 | Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 201-206. | 1.3 | 8 |
| 57 | Muscarinic Receptor Binding of Imidafenacin in the Human Bladder Mucosa and Detrusor and Parotid Gland. LUTS: Lower Urinary Tract Symptoms, 2011, 3, 64-68. | 0.6 | 7 |
| 58 | Fesoterodine, Its Active Metabolite, and Tolterodine Bind Selectively to Muscarinic Receptors in Human Bladder Mucosa and Detrusor Muscle. Urology, 2013, 81, 920.e1-920.e5. | 0.5 | 7 |
| 59 | Muscarinic Receptor Binding of the Novel Radioligand, [3H]Imidafenacin in the Human Bladder and Parotid Gland. Journal of Pharmacological Sciences, 2014, 124, 40-46. | 1.1 | 7 |
| 60 | Muscarinic Receptor Binding in Rat Bladder Urothelium and Detrusor Muscle by Intravesical Solifenacin. Biological and Pharmaceutical Bulletin, 2016, 39, 1167-1171. | 0.6 | 7 |
| 61 | Comparative Study on Pharmacokinetics and in Vivo .ALPHA.1-Adrenoceptor Binding of (3H)Tamsulosin and (3H)Prazosin in Rats.. Biological and Pharmaceutical Bulletin, 1999, 22, 412-417. | 0.6 | 6 |
| 62 | Up-regulation of nicotinic and muscarinic receptor mRNA in rat bladder by repeated administration of nicotine in relation to the pharmacokinetics. Life Sciences, 2011, 89, 343-348. | 2.0 | 6 |
| 63 | Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy. Journal of Pharmacy and Pharmacology, 2010, 63, 58-64. | 1.2 | 5 |
| 64 | Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamideâ€Induced Cystitis. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 57-63. | 0.6 | 5 |
| 65 | Muscarinic Receptor Binding and Plasma Drug Concentration after the Oral Administration of Propiverine in Mice. LUTS: Lower Urinary Tract Symptoms, 2010, 2, 43-49. | 0.6 | 4 |
| 66 | Endothelin-1 Receptors in Rat Tissues: Characterization by Bosentan, Ambrisentan and CI-1020. Biological and Pharmaceutical Bulletin, 2014, 37, 461-465. | 0.6 | 3 |
| 67 | Characterization of muscarinic and P2X receptors in the urothelium and detrusor muscle of the rat bladder. Journal of Pharmacological Sciences, 2016, 131, 58-63. | 1.1 | 3 |
| 68 | Characterization of muscarinic receptor binding by the novel radioligand, [3H]imidafenacin, in the bladder and other tissues of rats. Journal of Pharmacological Sciences, 2016, 131, 184-189. | 1.1 | 3 |
| 69 | Clinical Effects of Formulated Food of <scp>P</scp>eucedanum japonicum Extract and Saw Palmetto Extract in Male Patients with Lower Urinary Tract Symptoms. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 167-174. | 0.6 | 3 |
| 70 | Muscarinic receptor binding of fesoterodine, 5-hydroxymethyl tolterodine, and tolterodine in rat tissues after the oral, intravenous, or intravesical administration. Journal of Pharmacological Sciences, 2019, 140, 73-78. | 1.1 | 3 |
| 71 | Effects of saw palmetto extract on the vanilloid receptor <scp>TRPV1</scp>. LUTS: Lower Urinary Tract Symptoms, 2022, 14, 117-121. | 0.6 | 3 |
| 72 | Bladder Endothelin-1 Receptor Binding of Bosentan and Ambrisentan. Journal of Pharmacological Sciences, 2014, 124, 86-91. | 1.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Effects of Saw Palmetto Extract on Urodynamic Function and Receptors in the Lower Urinary Tract. Japanese Journal of Complementary and Alternative Medicine, 2007, 4, 41-50. | 1.0 | 2 |
| 74 | Comparative characterization of Î²-adrenoceptors in the bladder, heart, and lungs of rats: Alterations in spontaneously hypertensive rats. Journal of Pharmacological Sciences, 2022, 148, 51-55. | 1.1 | 2 |
| 75 | Beneficial Effects of Saw Palmetto Fruit Extract on Urinary Symptoms in Japanese Female Subjects by a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 2022, 14, 1190. | 1.7 | 2 |
| 76 | Beneficial Effects of Gosha-jinki-gan and Green Tea Extract in Rats With Chemical Cystitis. Journal of Pharmacological Sciences, 2013, 122, 270-277. | 1.1 | 1 |
| 77 | 5th International Symposium on receptor mechanisms, signal transduction and drug effects. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 267-268. | 1.4 | 0 |
| 78 | Editorial Comment to Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosisâ€induced chronic bladder ischemia. International Journal of Urology, 2012, 19, 675-675. | 0.5 | 0 |
| 79 | Antiâ€Tumor Effects and Pharmacokinetics of Sâ€40542, a Novel Nonâ€Steroidal Antiâ€Androgen, in Mice. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 44-51. | 0.6 | 0 |
| 80 | Direct inÂvitro and inÂvivo demonstration of muscarinic receptor binding by the novel radioligand, [3H]5-hydroxymethyltolterodine, in the bladder and other tissues of rats. Journal of Pharmacological Sciences, 2020, 142, 127-130. | 1.1 | 0 |